Your browser is no longer supported. Please, upgrade your browser.
ALBO Albireo Pharma, Inc. monthly Stock Chart
ALBO [NASD]
Albireo Pharma, Inc.
Index- P/E- EPS (ttm)-6.15 Insider Own0.30% Shs Outstand15.70M Perf Week4.19%
Market Cap704.78M Forward P/E- EPS next Y-8.16 Insider Trans- Shs Float15.30M Perf Month12.69%
Income-90.40M PEG- EPS next Q-1.98 Inst Own91.30% Short Float4.44% Perf Quarter34.23%
Sales12.00M P/S58.73 EPS this Y-28.00% Inst Trans43.58% Short Ratio1.75 Perf Half Y33.05%
Book/sh13.48 P/B2.69 EPS next Y-9.40% ROA-42.90% Target Price- Perf Year64.75%
Cash/sh14.36 P/C2.53 EPS next 5Y- ROE-71.20% 52W Range11.26 - 49.00 Perf YTD42.84%
Dividend- P/FCF- EPS past 5Y18.10% ROI-65.60% 52W High-25.90% Beta1.63
Dividend %- Quick Ratio13.50 Sales past 5Y- Gross Margin- 52W Low222.47% ATR1.73
Employees55 Current Ratio13.50 Sales Q/Q50.00% Oper. Margin- RSI (14)58.49 Volatility5.40% 5.45%
OptionableYes Debt/Eq0.00 EPS Q/Q-13.30% Profit Margin- Rel Volume0.20 Prev Close36.95
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume388.90K Price36.31
Recom1.50 SMA206.14% SMA504.57% SMA20034.71% Volume75,923 Change-1.73%
Aug-19-20Reiterated H.C. Wainwright Buy $64 → $50
Jul-31-20Initiated Piper Sandler Overweight $45
Jun-25-20Initiated Robert W. Baird Outperform $52
Feb-28-19Initiated H.C. Wainwright Buy $62
Apr-20-18Initiated Jefferies Buy $50
Nov-15-17Initiated ROTH Capital Buy $92
Jul-18-17Initiated Needham Buy $35
Jun-30-17Initiated Wedbush Outperform $58
Feb-16-17Initiated Ladenburg Thalmann Buy $40
Nov-20-20 10:45AM  
Nov-13-20 08:05AM  
Nov-12-20 08:00AM  
Nov-07-20 07:21AM  
Nov-05-20 07:30AM  
Nov-02-20 08:00AM  
Oct-23-20 09:20AM  
Oct-20-20 09:03AM  
Oct-05-20 08:30AM  
Oct-02-20 04:30PM  
Sep-19-20 07:00AM  
Sep-15-20 11:28AM  
Sep-09-20 09:16PM  
10:19AM  
10:08AM  
07:23AM  
Sep-08-20 04:01PM  
12:34PM  
06:30AM  
Sep-07-20 04:36PM  
Sep-03-20 08:47AM  
Aug-27-20 08:04AM  
Aug-21-20 09:00AM  
Aug-19-20 10:17AM  
Aug-18-20 04:40PM  
Aug-06-20 07:30AM  
Jul-30-20 04:01PM  
08:00AM  
Jul-27-20 11:42PM  
Jul-20-20 08:00AM  
Jul-14-20 07:30AM  
Jul-13-20 09:57AM  
Jul-10-20 08:40AM  
Jul-05-20 11:02PM  
Jul-01-20 10:23AM  
Jun-10-20 08:00AM  
Jun-09-20 07:30AM  
May-26-20 08:00AM  
May-12-20 06:29AM  
May-11-20 06:25AM  
May-08-20 03:30AM  
May-07-20 07:45AM  
07:30AM  
May-03-20 08:34AM  
Apr-30-20 09:47AM  
Apr-07-20 08:30AM  
Mar-10-20 08:30AM  
Mar-04-20 05:05AM  
Mar-02-20 07:30AM  
Feb-29-20 02:52PM  
Feb-27-20 09:12AM  
08:00AM  
Feb-26-20 08:30AM  
Feb-24-20 08:30AM  
Feb-03-20 04:01PM  
Jan-29-20 09:57PM  
04:06PM  
04:01PM  
Jan-23-20 08:00AM  
Dec-19-19 09:51PM  
09:17AM  
Dec-17-19 05:06AM  
Nov-14-19 08:30AM  
Nov-06-19 02:51PM  
07:30AM  
Nov-04-19 08:30AM  
Nov-02-19 09:26AM  
Nov-01-19 08:30PM  
Oct-30-19 08:00AM  
Oct-03-19 08:00AM  
Sep-30-19 09:23AM  
Sep-18-19 06:05AM  
Sep-03-19 08:30AM  
Aug-09-19 03:23AM  
Aug-08-19 07:30AM  
Aug-06-19 08:30AM  
Aug-01-19 08:30AM  
Jul-30-19 10:38AM  
Jul-09-19 04:05PM  
Jun-28-19 09:41PM  
Jun-20-19 09:24AM  
08:00AM  
Jun-07-19 07:00AM  
May-29-19 07:30AM  
May-23-19 07:30AM  
May-09-19 07:23PM  
May-02-19 08:30AM  
Apr-13-19 07:30AM  
Apr-11-19 07:30AM  
Apr-01-19 07:30AM  
Mar-27-19 08:48AM  
Mar-21-19 08:30AM  
Mar-07-19 03:15PM  
07:30AM  
Mar-04-19 08:30AM  
Feb-28-19 08:30AM  
Feb-27-19 08:30AM  
Feb-25-19 08:00AM  
Feb-07-19 12:38PM  
Jan-22-19 08:30AM  
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of gastrointestinal diseases. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Horn Patrick TaylorChief Medical OfficerOct 22Sale34.55893,0754,285Oct 23 04:21 PM
Duncan JasonChief Legal Officer and GCOct 22Sale34.71893,0893,781Oct 23 04:19 PM
Harford Simon N.R.CFO and TreasurerOct 12Sale37.30903,3574,616Oct 13 04:06 PM
Stephenson PamelaChief Commercial OfficerSep 25Sale33.2045114,97322,367Sep 25 05:05 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 14Buy40.00400,00016,000,0002,360,139Sep 15 08:30 AM
Carter Martha J.Chief Regulatory OfficerSep 11Option Exercise24.9810,000249,75310,000Sep 15 04:18 PM
Carter Martha J.Chief Regulatory OfficerSep 11Sale40.0310,000400,3000Sep 15 04:18 PM
Carter Martha J.Chief Regulatory OfficerSep 10Option Exercise24.0710,000240,70310,000Sep 10 09:02 PM
Carter Martha J.Chief Regulatory OfficerSep 10Sale42.4110,000424,1000Sep 10 09:02 PM
Carter Martha J.Chief Regulatory OfficerSep 09Option Exercise20.4010,000204,02510,000Sep 10 09:02 PM
Carter Martha J.Chief Regulatory OfficerSep 09Sale38.9710,000389,6500Sep 10 09:02 PM
Duncan JasonChief Legal Officer and GCSep 08Option Exercise24.043,50084,1407,870Sep 10 08:54 PM
Carter Martha J.Chief Regulatory OfficerSep 08Option Exercise19.1910,000191,90010,000Sep 10 09:02 PM
Carter Martha J.Chief Regulatory OfficerSep 08Sale45.5510,000455,5000Sep 10 09:02 PM
Duncan JasonChief Legal Officer and GCSep 08Sale45.554,000182,2003,870Sep 10 08:54 PM
Mattsson JanChief Scientific OfficerSep 08Sale45.5510,000455,50024,214Sep 10 08:49 PM
Duncan JasonChief Legal Officer and GCJul 22Sale25.80912,3484,370Jul 23 04:23 PM
Horn Patrick TaylorChief Medical OfficerJul 22Sale25.80912,3484,374Jul 23 04:15 PM
Harford Simon N.R.CFO and TreasurerJul 10Sale25.56922,3524,706Jul 10 05:50 PM
Stephenson PamelaChief Commercial OfficerJun 25Sale30.7939712,22422,818Jun 26 05:02 PM
Horn Patrick TaylorChief Medical OfficerApr 22Sale17.64921,6234,465Apr 24 05:22 PM
Duncan JasonChief Legal Officer and GCApr 22Sale17.68921,6274,461Apr 24 05:20 PM
Harford Simon N.R.CFO and TreasurerApr 13Sale16.52971,6024,798Apr 13 08:57 PM
Stephenson PamelaChief Commercial OfficerMar 25Sale17.601,78531,41623,215Mar 25 04:43 PM
PERCEPTIVE ADVISORS LLC10% OwnerFeb 03Buy21.00255,8095,371,9891,960,139Feb 04 08:00 AM
Horn Patrick TaylorChief Medical OfficerJan 22Sale24.2944310,7604,557Jan 23 07:28 PM
Duncan JasonChief Legal Officer and GCJan 22Sale23.9744710,7154,553Jan 23 07:22 PM
Harford Simon N.R.CFO and TreasurerJan 10Sale27.201052,8564,895Jan 14 04:18 PM